Search

Displaying results 4291 - 4300 of 10000 in total
  1. Drug

    Oxibendazole

    go.drugbank.com/drugs/DB04910
    ExperimentalVet approved

    Oxibendazole is a polymerase inhibitor in phase III trials for the treatment of helminth intestinal infections.

    Synonyms: Methyl 5-n-propoxy-2-benzimidazole carbamate
  2. Drug

    TAS-108

    go.drugbank.com/drugs/DB05966
    Investigational

  3. Drug

    DDP-200

    go.drugbank.com/drugs/DB05919
    Experimental

    DDP200 is developed by Dynogen for the treatment of non-incontinent form of overactive bladder (OAB) with particular focus on both male and female patients with urinary frequency, urinary urgency and nocturia

  4. Drug

    INGN 225

    go.drugbank.com/drugs/DB05325
    Investigational

    INGN 225 is currently in Phase 1/2 trials in patients with small cell lung cancer and breast cancer. … INGN 225 is a therapeutic consisting of a cancer patient's own immune cells treated with an adenovector carrying the human p53 gene, Ad-p53.

  5. Drug

    INCB13739

    go.drugbank.com/drugs/DB05064
    Investigational

    It is an orally available small molecule inhibitor of 11beta-HSD1 (11-beta hydroxysteroid dehydrogenase type 1). 11beta-HSD1 is an enzyme that appears to be critical to the development of type 2 diabetes

  6. Drug

    S-8510

    go.drugbank.com/drugs/DB06504
    Experimental

    S-8510 / SB-737552 is a BZD inverse agonist investigated for the treatment of Alzheimer’s disease and mild to moderate senile dementia. It was being codeveloped by Shionogi and GlaxoSmithKline.

  7. Drug

    Adakitug

    go.drugbank.com/drugs/DB05484
    Investigational

    HuMax-Inflam was also effective in reducing disease activity in palmoplantar pustulosis patients in a clinical study. … In pre-clinical studies, HuMax-Inflam has been shown to inhibit tumor growth in tumor models using primary human tumors in immunodeficient mice.

  8. Drug

    C31G

    go.drugbank.com/drugs/DB05398
    Investigational

    is a potent broad spectrum antimicrobial agent, effective against gram positive and gram negative bacteria, yeast and fungi.C31G, vaginal gel is developed by Biosyn Inc. and has commenced enrollment in

  9. Drug

    Bioymifi

    go.drugbank.com/drugs/DB17493
    Experimental

    Upon binding to the death receptor 5 (DR5) on cancer cells, bioymifi triggers apoptosis, possibly through a caspase-dependent pathway. Bioymifi is currently being investigated as an anti-tumor agent.

  10. Drug

    Alpha-1-proteinase inhibitor

    go.drugbank.com/drugs/DB00058
    ApprovedInvestigational

    Human alpha-1 proteinase inhibitor or alpha-1-antitrypsin, prepared from human plasma via Cohn alcohol fractionation followed by PEG and zinc chloride fractionation.